Integrated Diagnostics Holdings Valuation

Q: What is the Fair Price of IDHC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

IDHC ($0.38) is trading below our estimate of [[fair value]] ($2.15)

Is IDHC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of IDHC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: IDHC ($0.38) is trading below our estimate of fair value ($2.15)

Significantly Below Fair Value: IDHC is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for IDHC?

Key metric: As IDHC is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for IDHC. This is calculated by dividing IDHC's market cap by their current earnings.
What is IDHC's PE Ratio?
PE Ratio	13.4x
Earnings	ج.م817.28m
Market Cap	ج.م11.26b

IDHC key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	2.5x
Enterprise Value/EBITDA	9.8x
PEG Ratio	0.6x

Price to Earnings Ratio vs Peers

How does IDHC's PE Ratio compare to its peers?

The above table shows the PE ratio for IDHC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	20x
KOO Kooth	13.9x	11.0%	UK£60.2m
PHSC PHSC	9.7x	n/a	UK£2.4m
TSTL Tristel	32.3x	17.5%	UK£209.7m
EKF EKF Diagnostics Holdings	23.9x	n/a	UK£114.3m
IDHC Integrated Diagnostics Holdings	13.4x	23.7%	US$220.9m

Price-To-Earnings vs Peers: IDHC is good value based on its Price-To-Earnings Ratio (13.4x) compared to the peer average (22.8x).

Price to Earnings Ratio vs Industry

How does IDHC's PE Ratio compare vs other companies in the European Healthcare Industry?

2 Companies	Price / Earnings	Estimated Growth	Market Cap

2 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: IDHC is good value based on its Price-To-Earnings Ratio (13.4x) compared to the European Healthcare industry average (18.2x).

Price to Earnings Ratio vs Fair Ratio

What is IDHC's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

IDHC PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	13.4x
Fair PE Ratio	32.9x

Price-To-Earnings vs Fair Ratio: IDHC is good value based on its Price-To-Earnings Ratio (13.4x) compared to the estimated Fair Price-To-Earnings Ratio (32.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst IDHC forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	US$0.38	US$0.56 +47.5%	19.7%	US$0.67	US$0.45	n/a	2
Nov ’25	US$0.50	US$0.56 +13.5%	20.4%	US$0.68	US$0.45	n/a	2
Oct ’25	US$0.38	US$0.56 +49.4%	20.0%	US$0.68	US$0.45	n/a	2
Sep ’25	US$0.37	US$0.56 +50.4%	20.0%	US$0.68	US$0.45	n/a	2
Aug ’25	US$0.32	US$0.57 +79.8%	20.5%	US$0.68	US$0.45	n/a	2
Sep ’24	US$0.44	US$0.84 +89.7%	37.9%	US$1.15	US$0.52	US$0.37	2
Aug ’24	US$0.57	US$0.84 +46.8%	37.9%	US$1.15	US$0.52	US$0.32	2
Jul ’24	US$0.48	US$0.89 +85.2%	29.2%	US$1.15	US$0.63	US$0.30	2
Jun ’24	US$0.43	US$0.89 +106.7%	29.2%	US$1.15	US$0.63	US$0.31	2
May ’24	US$0.45	US$0.89 +97.3%	29.2%	US$1.15	US$0.63	US$0.31	2
Apr ’24	US$0.46	US$0.89 +93.0%	29.2%	US$1.15	US$0.63	US$0.40	2
Mar ’24	US$0.52	US$0.91 +74.4%	29.0%	US$1.17	US$0.64	US$0.37	2
Feb ’24	US$0.56	US$0.77 +37.0%	6.8%	US$0.82	US$0.72	US$0.34	2
Jan ’24	US$0.63	US$0.85 +33.8%	5.6%	US$0.91	US$0.79	US$0.35	3
Dec ’23	US$0.70	US$0.90 +28.2%	3.5%	US$0.93	US$0.85	US$0.32	3
Nov ’23	US$0.78	US$1.28 +63.7%	20.1%	US$1.72	US$1.08	US$0.37	4

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

Fagron

€1.3b

A pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide.

0HNZ

€18.33

-2.2%

6.3%

Guerbet

€334.1m

Engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions.

0ELV

€26.50

-8.0%

42.5%

Arjo

SEK 9.0b

Develops and sells medical devices and solutions for patients for clinical and financial outcomes for healthcare in Europe, Asia and Pacific, South America, Africa, and internationally.

0HQ8

SEK 32.94

-6.2%

-11.6%